University of Maryland School of Medicine, University of Maryland at Baltimore, Baltimore, Maryland, USA.
Department of Family Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
Helicobacter. 2022 Jun;27(3):e12894. doi: 10.1111/hel.12894. Epub 2022 Apr 28.
Although endemic to much of the global population, few studies have examined Helicobacter pylori (H. pylori) in US refugee populations. This study investigates the prevalence of H. pylori infection and barriers to treatment in the International Family Medicine Clinic (IFMC), a primary care refugee clinic, in central Virginia.
We conducted a chart review of 188 refugee patients of the IFMC who were referred for an H. pylori test between January 1, 2019, and December 31, 2020. Recorded measures included patient demographics, H. pylori test result, treatment of initial infection, completion of test of cure (TOC), TOC results, salvage therapy, and barriers to treatment. Binary logistic regression was performed to examine the association between demographic factors and H. pylori test results.
Of the 171 patients who completed an H. pylori test, 94 tested positive (54.9%). Of the 93 patients that were subsequently treated, 76 were treated with clarithromycin triple therapy (82%). Forty-eight patients (52%) completed a TOC after completing treatment, and 21 (43%) of these patients remained positive, indicating persistent infection. Eighteen patients (90%) who remained positive for H. pylori were subsequently treated with quadruple therapy. Patients under 18 (OR = 0.25, p < 0.01) and patients with a history of previous H. pylori (OR = 0.44, p < 0.05) were less likely to have positive results on initial H. pylori testing. Common barriers to treatment included pregnancy, religious observance (e.g., fasting), and health system complications (e.g., prior authorization for medications, cost of treatment).
The prevalence of H. pylori among refugees at the IFMC was higher than the overall prevalence estimate for the United States, which is consistent with previous studies. This work represents an updated picture of H. pylori prevalence among refugees in the United States and contributes to the identification of treatment barriers.
尽管全球大部分地区的人群都存在幽门螺杆菌(H. pylori)感染,但很少有研究关注美国难民群体中的 H. pylori 感染情况。本研究旨在调查弗吉尼亚州中部国际家庭医学诊所(IFMC)——一家初级保健难民诊所——中 H. pylori 感染的流行情况和治疗障碍。
我们对 2019 年 1 月 1 日至 2020 年 12 月 31 日期间因疑似 H. pylori 感染而在 IFMC 就诊的 188 名难民患者进行了病历回顾。记录的指标包括患者人口统计学特征、H. pylori 检测结果、初始感染的治疗情况、治疗后复查(TOC)的完成情况、TOC 结果、挽救治疗以及治疗障碍。采用二项逻辑回归分析人口统计学因素与 H. pylori 检测结果之间的关系。
在完成 H. pylori 检测的 171 名患者中,94 名检测结果呈阳性(54.9%)。在随后接受治疗的 93 名患者中,76 名接受了克拉霉素三联疗法(82%)。48 名患者(52%)在完成治疗后完成了 TOC,其中 21 名患者(43%)仍为阳性,表明存在持续性感染。18 名(90%)H. pylori 持续阳性的患者随后接受了四联疗法治疗。18 岁以下的患者(OR=0.25,p<0.01)和有 H. pylori 既往感染史的患者(OR=0.44,p<0.05)初始 H. pylori 检测结果阳性的可能性较低。治疗障碍包括妊娠、宗教信仰(如禁食)和医疗系统并发症(如药物的事先授权、治疗费用)。
IFMC 难民中 H. pylori 的流行率高于美国的总体流行率估计值,这与既往研究结果一致。本研究代表了美国难民中 H. pylori 流行情况的最新数据,有助于确定治疗障碍。